白介素-34通过多配体蛋白聚糖1和巨噬细胞集落刺激因子受体重编程类风湿关节炎巨噬细胞的糖酵解与破骨表型
该研究探讨白介素-34(IL-34)在类风湿关节炎(RA)中的作用机制。IL-34通过多配体蛋白聚糖1激活巨噬细胞集落刺激因子受体(M-CSFR)磷酸化,将RA初始细胞重编程为CD14+CD86+GLUT1+ M34巨噬细胞,表达高水平IL-1β、CXCL8和CCL2,并增强糖酵解活性。IL-34局部表达通过扩增糖酵解F4/80+iNOS+巨噬细胞群引发关节炎,吸引成纤维细胞和极化Th1/Th17细胞,而多配体蛋白聚糖1缺陷或糖酵解抑制可减轻IL-34诱导的关节炎。
要点
- IL-34通过多配体蛋白聚糖1和M-CSFR重编程RA巨噬细胞为高表达IL-1β、CXCL8、CCL2的M34表型
- M34巨噬细胞糖酵解增强,依赖GLUT1、c-Myc和HIF-1α转录上调
- 多配体蛋白聚糖1缺陷或糖酵解抑制可减轻IL-34诱导的关节炎和骨破坏
核心结论
- IL-34是重编程高代谢M34巨噬细胞并促进其与T效应细胞交叉调节、推动RA炎性骨破坏的新型内源性因子。
研究设计与样本
- 利用RA和临床前模型,在关节巨噬细胞、成纤维细胞和T效应细胞中阐明IL-34的作用机制。
主要发现
- 多配体蛋白聚糖1激活IL-34诱导的M-CSFR磷酸化,将RA初始细胞重编程为CD14+CD86+GLUT1+ M34巨噬细胞,表达升高水平的IL-1β、CXCL8和CCL2。
- 小鼠M34巨噬细胞炎症表型伴随糖酵解活性增强,表现为GLUT1、c-Myc和HIF-1α转录上调及丙酮酸和L-乳酸分泌增加。
- IL-34局部表达通过扩增糖酵解F4/80阳性iNOS阳性巨噬细胞群引发关节炎,进而吸引成纤维细胞和极化Th1/Th17细胞。
- 小鼠M34巨噬细胞与Th1/Th17细胞交叉对话拓宽炎症和代谢表型,扩大IL-34致病性。
- 与野生型小鼠相比,RAG-/-小鼠中IL-34引发的关节炎症减轻。
关键数值与推荐
- 多配体蛋白聚糖1缺陷通过干扰关节糖酵解M34巨噬细胞和破骨细胞重塑减轻IL-34诱导的关节炎。
- 2-脱氧-D-葡萄糖抑制糖酵解可逆转IL-34通过HIF-1α和c-Myc诱导触发的关节肿胀和代谢重编程。
临床怎么用
- 靶向IL-34-多配体蛋白聚糖1-M-CSFR轴或糖酵解可能为RA提供治疗策略。
局限性
- 机制主要基于RA和临床前模型,人体临床验证未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In rheumatoid arthritis (RA), elevated serum interleukin-34 (IL-34) levels are linked with increased disease severity. IL-34 binds to 2 receptors, macrophage colony-stimulating factor receptor (M-CSFR) and syndecan 1, which are coexpressed in RA macrophages. Expression of both IL-34 and syndecan 1 is strikingly elevated in the RA synovium, yet their mechanisms of action remain undefined. This study was undertaken to investigate the mechanism of action of IL-34 in RA. METHODS: To characterize the significance of IL-34 in immunometabolism, its mechanism of action was elucidated in joint macrophages, fibroblasts, and T effector cells using RA and preclinical models. RESULTS: Intriguingly, syndecan 1 activated IL-34-induced M-CSFR phosphorylation and reprogrammed RA naive cells into distinctive CD14+CD86+GLUT1+ M34 macrophages that expressed elevated levels of IL-1β, CXCL8, and CCL2. In murine M34 macrophages, the inflammatory phenotype was accompanied by potentiated glycolytic activity, exhibited by transcriptional up-regulation of GLUT1, c-Myc, and hypoxia-inducible factor 1α (HIF-1α) and amplified pyruvate and l-lactate secretion. Local expression of IL-34 provoked arthritis by expanding the glycolytic F4/80-positive, inducible nitric oxide synthase (iNOS)-positive macrophage population, which in turn attracted fibroblasts and polarized Th1/Th17 cells. The cross-talk between murine M34 macrophages and Th1/Th17 cells broadened the inflammatory and metabolic phenotypes, resulting in the expansion of IL-34 pathogenicity. Consequently, IL-34-instigated joint inflammation was alleviated in RAG-/- mice compared to wild-type mice. Syndecan 1 deficiency attenuated IL-34-induced arthritis by interfering with joint glycolytic M34 macrophage and osteoclast remodeling. Similarly, inhibition of glycolysis by 2-deoxy-d-glucose reversed the joint swelling and metabolic rewiring triggered by IL-34 via HIF-1α and c-Myc induction. CONCLUSION: IL-34 is a novel endogenous factor that remodels hypermetabolic M34 macrophages and facilitates their cross-regulation with T effector cells to advance inflammatory bone destruction in RA.
引用
- Van Raemdonck K, Umar S, Palasiewicz K, et al. Interleukin-34 Reprograms Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor. Arthritis Rheumatol. 2021. PMID: 33982895. doi:10.1002/art.41792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。